Health · 1 views
Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease characterized by misfolded transthyretin (TTR) amyloid deposits in the heart muscle.
Source AI Summary Updated 1h 34m ago
Health 
Story intelligence Beta
Confidence Limited Single-outlet story
Views 1 Community interest
Brief read ~30 words
AI Summary
The CARDIO‑TTRansform trial of eplontersen in patients with transthyretin‑mediated amyloid cardiomyopathy failed to achieve its primary efficacy endpoint, as reported during a Hot Line session at the ESC Congress 2026.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial findsContinue reading
- Txn1 mutant rats: A valuable translational model of chronic kidney diseaseContinue reading
- Juul can sell updated e-cigarette with age-verification system, FDA saysContinue reading
- Estimates predict 2.7 million extra people living with type 1 diabetes globally by 2049Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow